Interestingly, an enhanced antitumor response with complete tumor regression was observed in 80% of the mice treated with HER2-DC1 i.t. in combination with both anti-HER2 antibodies 7.16.4 and 7.9.5 (figure 2D). Here, ERBB2 is linked to neoplasm.